Keyword: Verzenio (abemaciclib)
Only weeks ago, Merck's I-O superstar Keytruda whiffed in a key lung cancer trial. Now the therapy is facing pushback from England's cost watchdog.
If this year’s ASCO meeting was “quiet,” as some contended, this year’s ESMO was anything but.
Eli Lilly's hoping for a kick-start from new data showing Verzenio helps tough-to-treat breast cancer patients live longer.
Rather than routine use, Kisqali’s coverage on NHS is available only through the Cancer Drugs Fund, the same limitation Verzenio got in the field.
GSK's Shingrix nabs Chinese nod; Roche's Chugai invests $1.15 billion in new R&D site; Japanese authority warns of Verzenio's side effect.
Just amid a global retreat of Lartruvo, Eli Lilly's cancer portfolio suffers another setback as Verzenio runs into safety problems in Japan.
Novartis saw an opening in the U.K. market to gain ground on competitors to its breast cancer drug Kisqali. Now that door has swung shut.
After Eli Lilly lowered its sales and earnings projections, analysts demanded details about new products—including migraine drug Emgality.
NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.